<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293032</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13311</org_study_id>
    <secondary_id>NCI-2010-02342</secondary_id>
    <secondary_id>P30CA016059</secondary_id>
    <nct_id>NCT01293032</nct_id>
  </id_info>
  <brief_title>Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer</brief_title>
  <official_title>Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studied whether the Oncotype DX gene expression
      &quot;Recurrence Score&quot; (RS) would be useful for helping make a decision about which type of
      pre-operative treatment, hormone therapy or chemotherapy would be a better for patients with
      hormone responsive cancers that were not suitable for breast conserving surgery. The RS is
      currently used to predict the risk of distant recurrence and the benefit of the addition of
      chemotherapy to hormonal therapy in the adjuvant setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessed the feasibility of carrying out a large-scale multi-center trial in which recurrence
      score (RS) was used to select treatment type in the neoadjuvant setting. Whether patients
      with intermediate RS were willing to be randomized between hormonal and chemotherapy.

      The treatment received was not experimental and considered standard treatment for the type of
      cancer the participants had. What was experimental included the way in which they were
      assigned to a type of treatment. The design of this study was used to help determine if RS
      can be used to predict which type of treatment women with breast cancer are most likely to
      benefit from.

      OUTLINE: Patients are assigned to 1 of 3 groups based on RS following Oncotype Dx gene
      expression profiling.

        -  GROUP 1 (RS &lt; 11): Patients receive neoadjuvant hormonal therapy comprising tamoxifen
           (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months
           in the absence of disease progression or unacceptable toxicity.

        -  GROUP 2 (RS 11-25): Patients are randomized to 1 of 2 treatment arms:

             -  ARM 1: Patients receive neoadjuvant hormonal therapy as in group I.

             -  ARM 2: Patients receive 6-8 courses of neoadjuvant chemotherapy comprising an
                anthracycline/taxane based regimen over 4-6 months in the absence of disease
                progression or unacceptable toxicity.

        -  GROUP 3 (RS &gt; 25): Patients receive neoadjuvant chemotherapy as in group 2 arm 2.

      All patients undergo surgery and receive hormonal therapy for at least 5 years.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The primary purpose of this trial is to determine the feasibility of carrying out a large multi-center trial with a similar design. Feasibility, in terms of less than 1/3 of patients with intermediate (11-25) Recurrence Score (RS) who refused the assigned treatment (Group 2) or refused randomization between hormonal (Arm 1) or chemotherapy (Arm 2). The confidence interval will be 95%. The proportion (and 95% confidence interval) of patients with RS 11-25 who refuse the assigned treatment will be calculated.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Ductal Breast Carcinoma in Situ</condition>
  <condition>Lobular Breast Carcinoma in Situ</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIA Breast Cancer</condition>
  <condition>Stage IIB Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a Recurrence Score (RS) less than 11 (RS &lt;11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a high RS (&gt; 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant Therapy</intervention_name>
    <description>Undergo neoadjuvant therapy</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
    <other_name>Induction Therapy</other_name>
    <other_name>Neoadjuvant</other_name>
    <other_name>Preoperative Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo therapeutic conventional surgery</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
    <other_name>Correlative studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene Expression Analysis</intervention_name>
    <description>Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a &quot;Recurrence Score&quot; (RS).</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic Chemotherapy</intervention_name>
    <description>Undergo chemotherapy</description>
    <arm_group_label>Group 2 Arm 2 (RS 11-25)</arm_group_label>
    <arm_group_label>Group 3 (RS &gt; 25)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Citrate</intervention_name>
    <description>Undergo hormonal therapy</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>TAM</other_name>
    <other_name>tamoxifen</other_name>
    <other_name>TMX</other_name>
    <other_name>hormonal therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibition Therapy</intervention_name>
    <description>Undergo hormonal therapy</description>
    <arm_group_label>Group 1 (RS &lt; 11)</arm_group_label>
    <arm_group_label>Group 2 Arm 1 (RS 11-25)</arm_group_label>
    <other_name>Inhibition therapy, aromatase</other_name>
    <other_name>Aromatase Inhibition</other_name>
    <other_name>hormonal therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The treating surgeon must determine that breast conservation therapy (BCT) would be
             made more feasible by reducing tumor size using neoadjuvant systemic therapy

          -  The patient must have signed and dated an institutional review board (IRB) approved
             consent form that conforms to federal and institutional guidelines

          -  The patient must be female

          -  The patient must be greater than or equal to 18 years old

          -  The patient must have an Eastern Cooperative Oncology Group Score (ECOG) performance
             status of 0 or 1

          -  The diagnosis of invasive carcinoma of the breast must have been made by core needle
             biopsy

          -  The primary breast tumor must be &gt;= 2 cm by physical exam or imaging

          -  Ipsilateral axillary lymph nodes must be evaluated by imaging (MRI or ultrasound)
             within 6 weeks prior to randomization; If indicated for abnormal lymph nodes, fine
             needle aspirate (FNA) or core biopsy must be performed.

          -  The tumor must have been determined to be HER2-negative as follows:

               -  Fluorescent in situ hybridization (FISH)-negative (defined by ratio of HER2 to
                  Chromosome 17 centromere (CEP17) must be &lt; 2.2) or, if a ratio was not performed,
                  the HER2 gene copy number must be &lt; 4 per nucleus; or

               -  Chromogenic in situ hybridization (CISH) is performed, the result must indicate a
                  HER2 gene copy number of &lt; 6 per nucleus; or

               -  Immunohistochemistry (IHC) 0-1+; or

               -  IHC 2+ and FISH-negative or CISH-negative

          -  The tumor must have been determined to be ER+ and/or progesterone positive (PgR+)
             defined as &gt; 10% tumor staining by immunohistochemistry

          -  The patient must have been evaluated by a treating physician, reviewed and discussed
             by the multi-disciplinary breast team, and considered to be a candidate for
             chemotherapy

        Exclusion Criteria:

          -  FNA alone to diagnose the primary tumor

          -  Excisional biopsy or lumpectomy performed prior to randomization

          -  Surgical axillary staging procedure or sentinel node (SN) biopsy performed prior to
             registration

          -  Tumors clinically staged as including inflammatory breast cancer

          -  Ipsilateral cN2b or cN3 disease (patients with cN1 or cN2a disease are eligible)

          -  Definitive clinical or radiologic evidence of metastatic disease (Note: chest imaging
             [mandatory for all patients] and other imaging [if required] must have been performed
             within 6 weeks prior to randomization)

          -  Synchronous or metachronous contralateral invasive breast cancer; (patients with
             synchronous and/or metachronous contralateral ductal carcinoma in situ (DCIS) or
             lobular carcinoma in situ (LCIS) are eligible)

          -  HER2 test result of IHC 3+, regardless of FISH results, if performed

          -  Any history of ipsilateral invasive breast cancer or ipsilateral DCIS if treated with
             radiation therapy (RT); (patients with synchronous or metachronous ipsilateral LCIS
             are eligible)

          -  History of non-breast malignancies, except for in situ cancers treated only by local
             excision and basal cell and squamous cell carcinomas of the skin, within 5 years prior
             to randomization

          -  Treatment including RT, chemotherapy, and/or targeted therapy for the currently
             diagnosed breast cancer prior to registration

          -  Cardiac disease (history of and/or active disease) that would preclude the use of
             chemotherapy

          -  Pregnancy or lactation at the time of randomization; (Note: pregnancy testing must be
             performed within 2 weeks prior to randomization for women of childbearing potential)

          -  Other non-malignant systemic disease that would preclude the patient from receiving
             study treatment or would prevent required follow-up

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements

          -  Use of any investigational product within 30 days prior to registration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry D. Bear, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Regional Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynchburg Hematology Oncology Clinic, Inc</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal , Hôtel-Dieu Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>VCU Massey Cancer Center</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <results_first_submitted>April 5, 2016</results_first_submitted>
  <results_first_submitted_qc>June 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2016</results_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estrogen Receptor Positive</keyword>
  <keyword>Progesterone Receptor Positive</keyword>
  <keyword>HER2/Neu Negative</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Once a patient consented to this study and was deemed eligible the core biopsy blocks or slides were sent to obtain the Oncotype DX Breast Cancer Assay. After the Recurrence Score(RS) results were available the subject was assigned to Group 1, 2, or 3. If assigned to Group 2 they were randomized to Arm 1 or Arm 2.</recruitment_details>
      <pre_assignment_details>5/64 subjects were not assigned or randomized to an arm: delayed oncotype result, core block lost, discrepancy in a bio-marker test, and two subjects deemed not eligible. There were 5 subjects who refused assigned randomization Group 2 Arm 2. 2/5 subjects who refused Group 2 Arm 2 were treated and evaluable for response on Arm 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (RS &lt; 11)</title>
          <description>Patients with a RS of less than 11 were assigned to Group 1. They received neoadjuvant hormonal therapy comprised of tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Arm 1 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 1 they received neoadjuvant hormonal therapy as in Group 1.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="P3">
          <title>Group 2 Arm 2 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 2 they received 6-8 courses of neoadjuvant chemotherapy comprised of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
        <group group_id="P4">
          <title>Group 3 (RS &gt; 25)</title>
          <description>Patients with a high RS (&gt; 25) were assigned to Group 3. They received chemotherapy, neoadjuvant chemotherapy as in Group 2 Arm 2.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Recurrence Score(RS)Assigned/Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Assigned/Randomized to Arm</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11">2/5 subjects who refused Arm 2(chemo) were treated with Arm 1(hormonal) and evaluable for response.</participants>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused Assigned Arm</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19">2/5 subjects who refused Arm 2(chemo) were treated with Arm 1(hormonal) and evaluable for response.</participants>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression, relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (RS &lt; 11)</title>
          <description>Patients with a Recurrence Score (RS) of less than 11 were assigned to Group 1. They received neoadjuvant hormonal therapy comprised of tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Arm 1 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 1 they received neoadjuvant hormonal therapy as in Group 1.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="B3">
          <title>Group 2 Arm 2 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 2 they received 6-8 courses of neoadjuvant chemotherapy comprised of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
        <group group_id="B4">
          <title>Group 3 (RS &gt; 25)</title>
          <description>Patients with a high RS (&gt; 25) were assigned to Group 3. They received chemotherapy, neoadjuvant chemotherapy as in Group 2 Arm 2.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.3125" spread="5.931426"/>
                    <measurement group_id="B2" value="63.64706" spread="11.5539"/>
                    <measurement group_id="B3" value="55.3125" spread="12.2556"/>
                    <measurement group_id="B4" value="60.64286" spread="7.312867"/>
                    <measurement group_id="B5" value="61.25423729" spread="10.52188724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment</title>
        <description>The primary purpose of this trial is to determine the feasibility of carrying out a large multi-center trial with a similar design. Feasibility, in terms of less than 1/3 of patients with intermediate (11-25) Recurrence Score (RS) who refused the assigned treatment (Group 2) or refused randomization between hormonal (Arm 1) or chemotherapy (Arm 2). The confidence interval will be 95%. The proportion (and 95% confidence interval) of patients with RS 11-25 who refuse the assigned treatment will be calculated.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Patients with an intermediate RS(11-25) assigned to Group 2, Arm 1, and Arm 2 were combined in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (RS 11-25)</title>
            <description>Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy, or treatment Arm 2, neoadjuvant chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment</title>
          <description>The primary purpose of this trial is to determine the feasibility of carrying out a large multi-center trial with a similar design. Feasibility, in terms of less than 1/3 of patients with intermediate (11-25) Recurrence Score (RS) who refused the assigned treatment (Group 2) or refused randomization between hormonal (Arm 1) or chemotherapy (Arm 2). The confidence interval will be 95%. The proportion (and 95% confidence interval) of patients with RS 11-25 who refuse the assigned treatment will be calculated.</description>
          <population>Patients with an intermediate RS(11-25) assigned to Group 2, Arm 1, and Arm 2 were combined in the analysis.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.051" upper_limit="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events (AEs) that are a result of standard diagnosis and treatment are not being collected and should not be reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (RS &lt; 11)</title>
          <description>Patients with a Recurrence Score (RS) of less than 11 were assigned to Group 1. They received neoadjuvant hormonal therapy comprised of tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Arm 1 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 1 they received neoadjuvant hormonal therapy as in Group 1.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
Hormonal therapy:
Tamoxifen Citrate (pre-menopausal women) OR
Aromatase Inhibition Therapy (post-menopausal women)</description>
        </group>
        <group group_id="E3">
          <title>Group 2 Arm 2 (RS 11-25)</title>
          <description>Patients with an intermediate RS (11-25) were assigned to Group 2. If randomized to Arm 2 they received 6-8 courses of neoadjuvant chemotherapy comprised of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
        <group group_id="E4">
          <title>Group 3 (RS &gt; 25)</title>
          <description>Patients with a high RS (&gt; 25) were assigned to Group 3. They received chemotherapy, neoadjuvant chemotherapy as in Group 2 Arm 2.
Treatment:
Neoadjuvant therapy
Therapeutic conventional surgery
Laboratory biomarker analysis/Correlative studies
Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
Systemic chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harry D Bear, MD, PhD</name_or_title>
      <organization>Virginia Commonwealth University/Massey Cancer Center</organization>
      <phone>804-828-9325</phone>
      <email>harry.bear@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

